Top Story

Open, robotic prostatectomy produce similar early functional outcomes

July 26, 2016

Robotic-assisted laparoscopic prostatectomy and open radical prostatectomy demonstrated similar 3-month postoperative outcomes for patients with localized prostate cancer, according to results of a randomized controlled phase 3 study.

Robot-assisted laparoscopic prostatectomy has been used since 2000; however, no head-to-head trial has yet compared the procedure with open radical prostatectomy.


Meeting Update: ASCO highlights therapeutic advances in multiple cancer subtypes

HemOnc Today, July 25, 2016
Meeting Update: ASCO highlights therapeutic advances in multiple cancer subtypes Supplement
In the Journals

USPSTF finds insufficient evidence in favor of screening for skin cancer

July 26, 2016
There is not sufficient evidence to recommend visual skin examination by a clinician in screening for skin cancer in asymptomatic adults, the U.S. Preventive Services…

Scientists receive grants for pancreatic cancer research

July 26, 2016
The American Association for Cancer Research and Pancreatic Cancer Action Network presented nine grants to early-career scientists who intend to pursue research in…

Chemoimmunotherapy combination ‘new standard’ for CNS lymphoma

July 26, 2016
The addition of rituximab to thiotepa and methotrexate–cytarabine increased the complete remission rate among patients with central nervous system lymphoma…
More News Headlines »

Management of Multiple Myeloma: Using Emerging Therapies with ASCT

This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Spectrum Pharmaceuticals, Inc.; and Takeda Oncology.

Multiple myeloma management has undergone profound changes in the past few decades, this is largely due to advances in…
More »
At Issue

VIDEO: Novel immune checkpoint blockade, vaccine-based therapies show promise in glioblastoma

July 19, 2016
More »
2016 ASCO Annual Meeting

2016 ASCO Annual Meeting


Optimizing the Use of Targeted Therapy in Advanced Melanoma: Where We Are and Where We Are Going

This activity is supported by an educational grant from Genentech.

Melanoma is the deadliest form of skin cancer. Historically, treatment options have been limited for patients with…
More »
Current Issues
View the Current Issue
HemOnc Today